Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder

Stopped The FDA determined that there is not adequate safety information to continue clinical investigations using ANS-6637 and Amygdala Neurosciences, the product company of ANS-6637, is no longer pursuing research with this compound.

Conditions

• Opioid-use Disorder

Interventions

• DRUG: ANS-6637
• DRUG: Placebo oral tablet

Sponsor

University of Maryland, Baltimore